Back

STRIDE Outcomes by Sexl

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Late-Breaking Clinical Science: cardiometabolic medicine Pharmacotherapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Professor Subodh Verma

St. Michael's Hospital, Toronto (Canada)

5 More presentations in this session

Presentation thumbnail
CONFIDENCE: Results by KDIGO risk category
Doctor M. Vaduganathan (Boston, US)
Slides Video
Presentation thumbnail
SGLT2i and AF
Doctor J. Sedighi (Giessen, DE)
Slides Video
Presentation thumbnail
SURMOUNT-5: Tirzepatide compared to Semaglutide in obesity for 10-year CVD risk reduction
Professor M. Mamas (Keele, GB)
Slides Video
Presentation thumbnail
Semaglutide is associated with lower risk of cardiovascular events compared with tirzepatide in patients with overweight or obesity and ASCVD and without diabetes in routine clinical practice
Ms L. Wilson (US)
Slides Video
Presentation thumbnail
Semaglutide and Tirzepatide in Patients with Heart Failure with Preserved Ejection Fraction
Doctor N. Kruger (Boston, US)

Access the full session

Session thumbnail
Late-Breaking Clinical Science: cardiometabolic medicine

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Effect of semaglutide in patients with type 2 diabetes and peripheral artery disease: an analysis of the STRIDE trial stratified by disease severity and age
thumbnail
Congress Presentation
Combined therapy of SGLT2i and GLP1ra reduces all-cause mortality in patients with type 2 diabetes with a higher impact on women
thumbnail
Congress Presentation
Baseline patient reported outcomes in patients with peripheral artery disease and type 2 diabetes from STRIDE: a phase 3, 52-week, randomised, double-blind, placebo-controlled trial

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources